Swedish spinout Epigenovo disclosed proof‑of‑concept for a high‑throughput single‑cell chromatin accessibility assay compatible with formalin‑fixed paraffin‑embedded (FFPE) tissues — scFFPE‑ATAC — in a recent Nature Communications paper and is raising capital to commercialize kitted products and services. The method uses a custom FFPE‑Tn5 and combinatorial indexing to generate tens of millions of cell barcodes per run, addressing a major translational bottleneck: lack of single‑cell epigenetic assays for archived clinical samples. Epigenovo’s CEO emphasized clinical translation potential, noting FFPE compatibility is critical for moving epigenetic profiling into routine pathology workflows.